IlluminOss Medical, a privately held, commercial stage medical device company pioneering the development of minimally invasive fracture fixation technologies, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for instruments used in the company’s proprietary Photodynamic Bone Stabilization System (PBSS). IlluminOss now holds 32 U.S. and international patents protecting the company’s innovative fracture fixation technology and its application on bones and procedures throughout the body.

The patents issued, “Apparatus and Methods for Repairing Craniomaxillofacial Bones,” “Apparatus for Delivery of Reinforcing Materials to Bone,” and “Photodynamic Bone Stabilization and Drug Delivery Systems,” indicate the breadth and forward thinking of the company’s intellectual property (IP) portfolio for the minimally invasive internal fixation of broken bones with PBSS.

“This strong and growing IP portfolio demonstrates that we are continuing to advance our innovative fracture fixation technologies as we expand our commercial efforts in Europe and work towards gaining regulatory approval in the United States,” said Robert Rabiner, founder and chief technology officer of IlluminOss. “With the addition of these three new patents, we can confidently say that our IP portfolio covers the whole body.”

Dirk Kuyper, president and CEO of IlluminOss, said, “In addition to the robustness of our patent estate, IlluminOss is gathering compelling clinical evidence that shows how our patient-customized approach to fracture repair has the potential to improve clinical outcomes.”

The minimally invasive PBSS quickly stabilizes bone fractures or prevents impending fractures through the first and only percutaneous, patient customized fracture fixation system that addresses a significant unmet need in pathological and osteoporotic fractures. Using PBBS, clinicians insert an angioplasty-like balloon into the intramedullary canal across the fracture site, which is then filled with a liquid monomer. Once the positioning of the implant is verified using fluoroscopy, light is delivered through a proprietary fiber to cure the monomer for rapid stabilization of the bone. This results in a customized fit to each patient’s specific anatomy providing rotational and torsional stability to the fracture. PBSS can be implanted for stand-alone primary fixation or in combination with screws or plates.

About IlluminOss Medical

IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, Photodynamic Bone Stabilization System (PBSS). This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The PBSS System utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company currently markets its products in under a CE Mark for approved clinical applications through both a direct sales force and distribution networks in Austria, Germany, Israel, Italy, the Netherlands, Spain, Switzerland and Turkey. Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology. Learn more at www.illuminoss.com.

The IlluminOss products are Investigational Devices; limited by Federal law to Investigational Use and are not approved for sale in the USA.

Media/investors contact:
David Connolly, 617-374-8800, Ext. 108